Evidence map›Paper›PMID 35620569›Full record

ArticleVaccine: X2022

Hiba Sabbar, Chafik Mahraoui, Magdalena Bastìas Garcià, Imane Jroundi

Open access · goldAbstract read
In one paragraph

Article in Vaccine: X, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Human vaccines & immunotherapeutics · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hiba SabbarUnit of Training and Research on Pediatric Infectious Diseases Targeted by Vaccines and Evaluation of Vaccines Policies, Department of Public Health and Social Accountability, School of Medicine and Pharmacy. University Mohammed V in Rabat, Morocco.
Chafik MahraouiPediatric Infectious Disease Ward, Hospital d'Enfants Rabat. University Hospital Ibn Sina. Rabat, Morocco.
Magdalena Bastìas GarciàIndependent Consultant on Immunization policies. Chile.
Imane JroundiUnit of Training and Research on Pediatric Infectious Diseases Targeted by Vaccines and Evaluation of Vaccines Policies, Department of Public Health and Social Accountability, School of Medicine and Pharmacy. University Mohammed V in Rabat, Morocco.
Mohammed V University · MACentre Hospitalier Ibn Sina · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of pneumococcal conjugate vaccines (PCVs) on invasive pneumococcal disease (IPD) burden has been extensively studied in children aged<5 years; however, a pooled estimation of the effect of PCVs on penicillin non-susceptible pneumococci (PNSP) has not yet been performed. We aimed to identify whether the introduction of PCV-10 and PCV-13 had led to the decrease of the overall PNSP rate in children < 5 years. We conducted a systematic review of published surveillance studies reporting the rate of PNSP rates in children < 5 in countries where PCV10/13 were introduced. The overall observed trend onwards the introduction of PCV-10 and PCV-13 is a decrease in PNSP among children < 5 years in surveillance sites located in PCV-13 countries. We identified an increase of PNSP rates (serotype 19A) in PCV-10 settings. Resistant NVT strains are emerging in IPD in children < 5 years mainly serotypes 24F, 15A, 11A and 33F along with serotype 19A in PCV-10 settings. Continuous surveillance is necessary in IPD in children under five to monitor the long-term effect of PCV-10 and PCV-13 on penicillin resistance trends.

Indexed as

Antibiotic resistanceAntimicrobial resistanceChildren under fiveDrug resistanceInvasive pneumococcal diseaseIPDPCV-10 PCV-13Penicillin non-susceptibilityPneumococcal conjugate vaccination

Identifiers

PMID35620569
PMCPMC9127579
OpenAlexW4280574357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.